Biodesix Reports Q2 2025 Earnings Results
Biodesix (BDSX) reported Q2 2025 earnings with total revenue of $20.0 million, up 12% year-over-year. The company saw growth in both lung diagnostics and Development Services, though it posted a net loss of $11.5 million. The results highlight strong revenue growth but also increased operating expenses and losses.
Topics: Cash Position Development Services Digital Ordering Gross Margin Lung Diagnostics Net Loss Operating Expenses Primary Care Revenue Growth Sales Team Expansion